Table 1.
Comparison of baseline data between the two groups.
| Item | Control group | Treatment group | p |
|---|---|---|---|
| N (cases) | 65 | 65 | – |
| M (cases) | 17 | 8 | 0.44 |
| F (cases) | 48 | 57 | |
| Age (years) | 40.32 ± 14.192 | 42.92 ± 13.467 | 0.81 |
| FT3 (pmol/l) | 14.90 (20.91) | 11.88 (17.12) | >0.05 |
| FT4 (pmol/l) | 38.08 (53.37) | 34.98 (51.89) | >0.05 |
| TSH (mIU/L) | 0.005 (0.004) | 0.005 (0.0035) | >0.05 |
| TGAb (IU/ML) | 87.35 (261.44) | 246.7 (493.76) | >0.05 |
| TPOAb (IU/ML) | 103.0 (310.0) | 129.4 (316.67) | >0.05 |
| TRAb (mIU/ML) | 8.83 (20.1) | 8.48 (20.06) | >0.05 |
| Symptom score | 33.51 ± 7.115 | 37.06 ± 6.619 | >0.05 |
| CD4+/CD25+ (%) | 9.3 (4.95) | 6.7 (5.45) | >0.05 |
| IL-10 (pg/ml) | 5.0 (0) | 5.0 (0.6) | >0.05 |
| IL-6 (pg/ml) | 2.2 (1.2) | 2.0 (0.6) | >0.05 |
| TNF-α (pg/ml) | 6.8 (6.1) | 8.76 (7.15) | >0.05 |
| IFN-γ (pg/ml) | 7.0 (4.95) | 6.3 (5.45) | >0.05 |